Assembly Biosciences Inc Market Cap ($405.58 Million)
Market Cap & Net Worth: Assembly Biosciences Inc (ASMB)
Assembly Biosciences Inc market cap. Assembly Biosciences Inc (NASDAQ:ASMB) has a market capitalization of $405.58 Million ($405.58 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12969 globally and #3202 in its home market, demonstrating a 1.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Assembly Biosciences Inc's stock price $19.92 by its total outstanding shares 20360596 (20.36 Million). Also see ASMB operating cash flow for how efficiently the company converts equity into cash flow.
Assembly Biosciences Inc Market Cap History (2015–2026)
Assembly Biosciences Inc market cap history from 2015 to 2026. Data shows change from $1.83 Billion to $404.57 Million (-15.37% CAGR). Check Assembly Biosciences Inc (ASMB) share price today for real-time trading data and today's change.
Index Memberships
Assembly Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.02% | #353 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1284 of 3165 |
Weight: Assembly Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Assembly Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Assembly Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ASMB net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
9.58x
Assembly Biosciences Inc's market cap is 9.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $11.06 Billion | $9.02 Million | -$42.81 Million | 1225.87x | N/A |
| 2018 | $5.53 Billion | $14.80 Million | -$90.75 Million | 373.32x | N/A |
| 2019 | $5.00 Billion | $15.96 Million | -$97.63 Million | 313.16x | N/A |
| 2020 | $1.48 Billion | $79.11 Million | -$62.15 Million | 18.69x | N/A |
| 2021 | $569.28 Million | $6.25 Million | -$129.85 Million | 91.03x | N/A |
| 2023 | $200.37 Million | $7.16 Million | -$61.23 Million | 27.97x | N/A |
| 2024 | $321.29 Million | $28.52 Million | -$40.18 Million | 11.27x | N/A |
| 2025 | $692.46 Million | $72.30 Million | -$6.12 Million | 9.58x | N/A |
Competitor Companies of ASMB by Market Capitalization
Companies near Assembly Biosciences Inc in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Assembly Biosciences Inc for a full breakdown of the balance sheet.
Key companies related to Assembly Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Assembly Biosciences Inc (2015–2026)
Market capitalization of Assembly Biosciences Inc from 2015 to today. Between 2015 and today, Assembly Biosciences Inc's market cap moved from $1.83 Billion to $ 404.57 Million, with a yearly change of -15.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $404.57 Million | -41.58% |
| 2025 | $692.46 Million | +115.53% |
| 2024 | $321.29 Million | +60.35% |
| 2023 | $200.37 Million | -36.92% |
| 2022 | $317.63 Million | -44.21% |
| 2021 | $569.28 Million | -61.49% |
| 2020 | $1.48 Billion | -70.43% |
| 2019 | $5.00 Billion | -9.55% |
| 2018 | $5.53 Billion | -50.01% |
| 2017 | $11.06 Billion | +272.43% |
| 2016 | $2.97 Billion | +61.78% |
| 2015 | $1.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Assembly Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $405.58 Million USD |
| MoneyControl | $405.58 Million USD |
| MarketWatch | $405.58 Million USD |
| marketcap.company | $405.58 Million USD |
| Reuters | $405.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more